Company / Income Tax
Vertex Pharmaceuticals Income Tax History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Income Tax
$690.0M
FY2025
5-year range
$388.3M / $910.4M
FY2021-FY2025
Trend
-12.0%
vs FY2024
Sector context
#9 of 204
Health Care
What the data says
Among 204 Health Care companies, Vertex Pharmaceuticals is in the bottom 4% for income tax. Income Tax has fluctuated over the past 10 years, ranging from -$1.5B in FY2018 to $910M in FY2022.
Based on SEC 10-K filings.
$690M in FY2025 with a 5-year CAGR of +11.2%. Top quartile in the Health Care sector.
Improved from $760M to $690M over the past 2 years.
Health Care sector context is included.
Income Tax over time
Growth rates
- 3-Year CAGR
- -8.8%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 204This company $690.0M Sector average $118.7M
▼
+481.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2025, income tax decreased 12.0% year-over-year.
- Ranks #9 out of 204 companies in the Health Care sector.
- Peak income tax was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Income TaxValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $690.0M | -12.0% |
| FY2024 | $784.1M | +3.1% |
| FY2023 | $760.2M | -16.5% |
| FY2022 | $910.4M | +134.5% |
| FY2021 | $388.3M | -4.2% |
| FY2020 | $405.2M | +85.8% |
| FY2019 | $218.1M | +114.7% |
| FY2018 | -$1.5B | -1285.4% |
| FY2017 | -$107.3M | -744.0% |
| FY2016 | $16.7M | -45.1% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026